Application Serial No.: 10/506,524

IN THE SPECIFICATION:

Please amend the specification as follows:

Please replace the paragraph at page 2, line 18 to page 3, line 2, with the following rewritten paragraph:

Therefore, the object of the present invention is to provide a conjugate of the hydrophilic polymer-multicarboxyl oligopeptide and drug molecule represented by the following formula:

P——X—
$$\left(-NH$$
—— CH —— C —— Z ——TA
$$\left(CHR_{i}\right)_{j}$$

$$C$$

$$Z$$

$$I$$

$$I$$

wherein:

P is a water-soluble hydrophilic polymer;

m is an integer from 2 to 12;

j is an integer from 1 to 6;

R_i is a group selected from the group consisting of H, C₁₋₁₂ alkyl, substituted aryl, aralkyl, heteroalkyl and substituted alkyl;

X is a linking group;

Z is a linking group selected from O and NH; and

TA is a drug molecule.

Please replace the paragraph at page 7, lines 6-23, with the following rewritten paragraph:

Application Serial No.: 10/506,524

Consequently, hydrophilic polymer-multioligopeptide can conjugate to the drug molecules in the same way to replace bio-organic molecules and overcome their shortcomings of short physiological half-time and short therapeutic duration. The hydrophilic polymer-multicarboxy oligopeptide of the present invention has the following formula:

P——X—
$$\left(-NH$$
— CH —— C —— C —— Z —— TA

$$\left(\begin{array}{c} CHR_{i})_{j} \\ C \end{array}\right)$$

$$C \longrightarrow O$$

$$C \longrightarrow O$$

$$C \longrightarrow TA$$

wherein:

P is a water soluble <u>hydrophilic</u> polymer, which may be polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyacrylmorpholine or their copolymer, and polyethylene glycol and its copolymer are preferred;

m is an integer of 2~12;

j is an integer of 1~6;

R_i is a group selected from the group consisting of H, C₁₋₁₂ alkyl, substituted aryl, aralkyl, heteroalkyl and substituted alkyl;

X is a linking group, preferably (CH₂)_i, (CH₂)_iOCO, (CH₂)_iNHCO and (CH₂)_iCO, wherein i is an integer of 1~10;

Z is a linking group selected from O and NH; and

TA is a drug molecule.

Please replace the paragraph under "ABSTRACT" on page 17 with the following rewritten paragraph:

The present invention relates to a conjugate of hydrophilic polymer-multicarboxyl oligopeptide and drug molecule of the following formula:

Application Serial No.: 10/506,524

$$P \longrightarrow X \longrightarrow (-NH \longrightarrow CH \longrightarrow C \longrightarrow_{m} Z \longrightarrow TA)$$

$$(CHR_{i})_{j}$$

$$C \longrightarrow O$$

$$Z$$

$$TA$$

wherein: P is a water soluble <u>hydrophilic</u> polymer; m is an integer of $2\sim12$; j is an integer of $1\sim6$; R_i is a group selected from H, C₁₋₁₂ alkyl, substituted aryl, aralkyl, heteroalkyl and substituted alkyl; X and Z are linking groups; and TA is drug molecule. The conjugate has low toxicity and an ability to carry more than one drug molecule to improve solubility, sustain and control drug release, and has a remarkably enhancing effect especially to antitumor drug such as paclitaxel and camptothecin etc.